Press releaseGlobe Newswire
AVITA Medical
RCEL · NASDAQ
$13.80+$0.66 (+5.02%)TodayMarket closed ·
Prev close $13.14
Latest news
- News
AVITA Medical Q2 2026 Earnings Call Transcript
- Press releaseGlobe Newswire
AVITA Medical Announces Positive PermeaDerm® Study Results Demonstrating 70% Economic Advantage over Allograft and Comparable Clinical Outcomes
- Press releaseGlobe Newswire
AVITA Medical to Host Investor Webinar Briefing
- News
12 Health Care Stocks Moving In Friday's Intraday Session
- News
12 Health Care Stocks Moving In Friday's Pre-Market Session
- News
12 Health Care Stocks Moving In Thursday's After-Market Session
- Press releaseGlobe Newswire
AVITA Medical Reports Second Quarter Results, Raises 2026 Revenue Guidance, and Expects Fourth Quarter Cash Flow Breakeven
- NewsAvi Kapoor
Why Celestica Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket
- Press releaseGlobe Newswire
AVITA Medical to Announce Second Quarter 2026 Financial Results
- Press releaseGlobe Newswire
AVITA Medical Highlights First U.K. Clinical Experience with RECELL GO at British Burn Association Annual Meeting
- Press releaseGlobe Newswire
AVITA Medical to Host Investor Webinar Briefing
- News
AVITA Medical Reports Q1 2026 Results: Full Earnings Call Transcript
- News
12 Health Care Stocks Moving In Thursday's After-Market Session
- Press releaseGlobe Newswire
AVITA Medical Reports First Quarter 2026 Financial Results
- Press releaseGlobe Newswire
AVITA Medical Names Cary Vance as Chief Executive Officer
- Press releaseGlobe Newswire
AVITA Medical Announces TGA Certification in Australia and Medsafe WAND Listing in New Zealand for RECELL GO
- Press releaseGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AVITA Medical Inc. - RCEL
- Press releaseGlobe Newswire
AVITA Medical Founder Fiona Wood Honored with Lifetime Achievement Award by American Burn Association
- Press releaseGlobe Newswire
AVITA Medical Announces Positive Interim Results from Cohealyx® Study Demonstrating Accelerated Time to Skin Grafting
- Press releaseGlobe Newswire
Bragar Eagel & Squire, P.C. Encourages Soleno, Avita, and Coty Investors to Contact the Firm Regarding Ongoing Investigations
- Press releaseGlobe Newswire
Bragar Eagel & Squire, P.C. Encourages Agilon, Soleno, Avita, and Coty Investors to Contact the Firm Regarding Ongoing Investigations
- Press releaseGlobe Newswire
Bragar Eagel & Squire, P.C. Encourages Agilon, Soleno, Avita, and Coty Investors to Contact the Firm Regarding Ongoing Investigations
- Press releaseGlobe Newswire
Bragar Eagel & Squire, P.C. Is Investigating Agilon, Soleno, Avita, and Coty and Encourages Investors to Contact the Firm
- News
Earnings Scheduled For November 6, 2025
- Press releaseBusiness Wire
Rosen Law Firm Encourages AVITA Medical, Inc. Investors to Inquire About Securities Class Action Investigation – RCEL
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AVITA Medical, Inc. - RCEL
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AVITA Medical, Inc. - RCEL
- Press releaseGlobe Newswire
AVITA MEDICAL INVESTIGATION: Bragar Eagel & Squire, P.C. Reminds AVITA Medical Investors to Contact the Firm Regarding the Ongoing Investigation on Behalf of Stockholders
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AVITA Medical, Inc. - RCEL
- Press releaseGlobe Newswire
AVITA REMINDER: Bragar Eagel & Squire, P.C. Reminds AVITA Medical Investors to Contact the Firm Regarding the Ongoing Investigation on Behalf of Stockholders
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AVITA Medical, Inc. - RCEL
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AVITA Medical, Inc. - RCEL
- Press releaseGlobe Newswire
AVITA (RCEL) INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into AVITA Medical, Inc. and Encourages Investors to Contact the Firm
- Press releaseGlobe Newswire
Securities Fraud Investigation Into AVITA Medical, Inc. (RCEL) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
- Press releaseGlobe Newswire
AVITA Medical, Inc. (RCEL) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
- Press releaseGlobe Newswire
Securities Fraud Investigation Into AVITA Medical, Inc. (RCEL) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AVITA Medical, Inc. - RCEL
- Press releaseGlobe Newswire
AVITA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating AVITA Medical, Inc. on Behalf of Avita Stockholders and Encourages Investors to Contact the Firm
- Press releaseGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AVITA Medical, Inc. - RCEL
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AVITA Medical, Inc. - RCEL
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AVITA Medical, Inc. - RCEL
- Press releaseGlobe Newswire
AVITA ALERT: Bragar Eagel & Squire, P.C. is Investigating AVITA Medical, Inc. on Behalf of Avita Stockholders and Encourages Investors to Contact the Firm
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AVITA Medical, Inc. - RCEL
- Press releaseBusiness Wire
RCEL Investors Have Opportunity to Join AVITA Medical, Inc. Fraud Investigation with the Schall Law Firm
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.